Studies showed that chemotherapeutic agents, including tamoxifen, bind to the estrogenic receptors and act as an antagonist in breast tissues but as an agonist in nearby tissues [23,24], therefore chemotherapeutic treatment for breast cancer patients is highly risky [25,26,27]. This evidence concerns the gene ESR1 and breast carcinoma.